Rani Therapeutics Holdings, Inc.·4

Jun 1, 4:09 PM ET

Bailey Vasudev Jaiprakash 4

4 · Rani Therapeutics Holdings, Inc. · Filed Jun 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Rani Therapeutics (RANI) Director Bailey Vasudev Jaiprakash Receives Award of 123,600 Shares

What Happened
Bailey Vasudev Jaiprakash, a director of Rani Therapeutics Holdings, Inc. (RANI), was granted a derivative award on May 28, 2026 covering 123,600 shares. The Form 4 reports an acquisition at $0.00 (transaction code A — award/grant). The filing identifies the award as shares subject to an option (see footnote).

Key Details

  • Transaction date: 2026-05-28; Form 4 filed 2026-06-01 (timely — within 2 business days).
  • Reported price: $0.00; transaction code: A (award/grant); reported as a derivative security.
  • Shares in grant: 123,600 shares.
  • Shares owned after transaction: not disclosed in the provided filing.
  • Footnote (F1): The shares subject to the option vest in full on the first anniversary of the grant date, subject to the reporting person’s continuous service; alternatively, vesting occurs earlier upon the company’s next annual stockholder meeting or a Change in Control (each subject to continuous service).

Context
This was an equity award (a derivative/option grant), not an open-market purchase or sale. There was no immediate cash paid per the filing (reported price $0.00); the economic value to the insider depends on future vesting and the company’s stock price. Awards to directors are common compensation and do not by themselves indicate the insider’s intent to buy or sell shares.

Insider Transaction Report

Form 4
Period: 2026-05-28
Transactions
  • Award

    Director Stock Option (Right to Buy)

    [F1]
    2026-05-28+123,600123,600 total
    Exercise: $0.95Exp: 2036-05-27Class A Common Stock (123,600 underlying)
Footnotes (1)
  • [F1]The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.
Signature
/s/ Svai Sanford, Attorney-in-Fact|2026-06-01

Documents

1 file
  • 4
    ownership.xmlPrimary

    4